Additional capital for AC BioScience

Additional capital for AC BioScience

25.5.2020 – Following last year’s seed round closing, Lausanne-based AC Bioscience has obtained additional capital of CHF1 million from undisclosed investors, bringing its total seed funds to CHF 2 million. The start-up develops personalized therapies for tumoral pathologies. Two lead molecules will enter clinical stage in early 2021.

read more